Clinical Trial Update: A Study to Assess the Efficacy, Safety and Pharmacokinetics of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy (SMA) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating nusinersen (ISIS 396443) for efficacy, safety, and pharmacokinetics in infants with spinal muscular atrophy has completed with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spinal Muscular Atrophy

Drugs mentioned

• Nusinersen (nusinersen)

Snippet

Sponsor: Biogen | Conditions: Spinal Muscular Atrophy | Phase 2 | Status: COMPLETED | Results posted: 2018-10-30